StratDeck

Two stocks in Healthcare

argenx vs Merck KGaA: profit, growth, debt and price compared

argenx is stronger on 4 of 6 figures: profit margin, sales growth, debt and price trend. Merck KGaA is stronger on 1: price for its expected profit.

Figures as of 18 November 2026Yahoo Finance
Explore argenx's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

argenx and Merck KGaA side by side
argenxARGX.BRMerck KGaAMRK.DE
Net marginStronger: 31.7%8.9%
Revenue growth, past yearStronger: +52.10%+5.80%
Debt to equityStronger: 0.6%38.1%
Forward P/E26.9×Stronger: 16.4×
Dividend yield—1.47%
AnalystsBuy · 23Buy · 14
From its 200-day averageStronger: +11.9%+11.7%

Share price over the past year

  • argenx+9.4%
  • Merck KGaA+32.5%

24 Nov 202518 Nov 2026

argenx or Merck KGaA: which is stronger?

  • ARGX.BR

    Which is more profitable?

    argenx keeps more of each sale as profit: 31.7% against 8.9%.

  • ARGX.BR

    Which is growing its sales faster?

    argenx is growing its sales faster: +52.10% over the past year, against +5.80%.

  • ARGX.BR

    Which has borrowed less?

    argenx has borrowed less: its debt is 0.6% of what its shareholders own, against 38.1% for Merck KGaA.

  • MRK.DE

    Which costs less for the profit it is expected to make?

    Merck KGaA costs less for the profit it is expected to make: 16.4× its forward earnings, against 26.9×.

  • Which pays more in dividends?

    Merck KGaA pays 1.47% a year in dividends for what a share costs, where argenx pays none.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • ARGX.BR

    Which is in the stronger price trend?

    argenx's price is in the stronger trend: 11.9% above its 200-day average, against 11.7% above.

What each company does

ARGX.BRargenx

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

Reports results on 25 February 2027

MRK.DEMerck KGaA

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.

Reports results on 4 March 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.